Navigation Links
Armetheon Completes $7.0 Million Series A Financing
Date:8/28/2014

MENLO PARK, Calif., Aug. 28, 2014 /PRNewswire/ -- Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The Series A round was co-led by AshHill Biomedical Investments and Hercules Bioventures with participation from investors that included Atheneos Capital and eminent biotech entrepreneur and pharmaceutical executive, Dr. Larry Hsu, the founder of Impax Laboratories.

Earlier this year the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial, TACT (Tecarfarin for AntiCoagulation Trial), for Tecarfarin, which is being investigated for all patients who require an oral anticoagulant (OAC), including patients with mechanical heart valves (MHV). Recent clinical guidelines from AHA/ACC recommend the use of a vitamin-K antagonist (VKA) for anticoagulation in patients with a MHV. The guidelines also recommend MHV over bioprosthetic heart valves for patients who are less than 60 years of age. The results from already completed clinical trials and TACT will form the basis of regulatory submission for Tecarfarin.

"The quality of our science and the team is reflected by the stellar syndicate of both institutional and angel investors in this over-subscribed Series A round," said M. (Ken) Kengatharan, PhD, Co-Founder, President & COO.

"The funds will be used to keep to our NDA filing timeline in 2017 for Tecarfarin," said Peter Milner MD, FACC Co-Founder and Chairman of Armetheon. "Tecarfarin, if approved, could become an important alternative VKA that is not metabolized via CYP enzymes or handled by P-glycoprotein.Studies have shown that existing OACs, including warfarin, interact with CYP-metabolizing enzymes or P-glycoprotein."  Milner previously co-founded both CV Therapeutics and ARYx Therapeutics, and currently serves as CEO of Heart Metabolics Ltd (Ireland).

In addition to Drs. Kengatharan and Milner, Armetheon's board includes Pascal Druzgala, PhD, Co-Founder, and industry veterans, Jon Saxe and Steven P. James, formerly CEO of Labrys Biologics, Inc. (recently acquired by Teva) and KAI Pharmaceuticals, Inc. (acquired by Amgen).

About Tecarfarin

Tecarfarin is being investigated for use as an oral, once-daily anticoagulant  inhibitor of Vitamin K epoxide reductase (VKOR, an important enzyme in the coagulation system) which avoids CYP450-dependent metabolism and renal elimination. In a phase 2 and a phase 2/3 (EMBRACE-AC) clinical studies,this drug candidate improved time in therapeutic range (TTR) in chronically anticoagulated patients. The effect of Tecarfarin on TTR will be further investigated in the TACT clinical trial.  TTR was chosen as the endpoint for these trials on the basis of evidence suggesting that better anticoagulation control (as measured by higher TTR) can protect patients from severe or even fatal adverse events. Tecarfarin is monitored using INR, and is being investigated for use without the need for CYP2C9 genotyping since Tecarfarin is not metabolized via the CYP-450 system. In pre-clinical and early clinical studies, the anticoagulant effect of Tecarfarin was reversed by existing and readily available antidotes for VKAs.

About Armetheon

Armetheon, Inc. is a privately held San Francisco Bay area based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced, successful biotech entrepreneurs and drug developers with funding from AshHill Biomedical investments (http://www.ashhill.net) and Atheneos Capital (http://www.atheneoscapital.com). Armetheon's two late-stage small molecule drug candidates are for use in the areas of oral anticoagulation and atrial fibrillation. Locust Walk Partners serves as the key strategic advisors to the company. For more information: www.armetheon.com.

Contact:
Binay Curtis (Galaxy Six Strategies): Binay(at)galaxysix(dot)com (for general inquiries)
Chris Ehrlich (Locust Walk Partners): Chris(at)locustwalkpartners(dot)com (for partnership inquiries)

Logo - http://photos.prnewswire.com/prnh/20140828/140818


'/>"/>
SOURCE Armetheon, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Microbial Discovery Group (MDG) in Franklin, WI Completes Expansion
2. MIT Spinoff LayerBio Completes Seed Round; Initiates Development of First Ophthalmology Product
3. Clinverse, Inc. Completes SOC 1 (SSAE 16) Type 2 Examination
4. Cambrex Manufacturing Facility Completes Successful US FDA Inspection
5. InstantGMP Completes Updates to v2.03 of their Manufacturing Execution System with Electronic Batch Records
6. AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
7. KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
8. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
9. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
10. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
Breaking Biology News(10 mins):